Related Experiment Video
Updated: Nov 28, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Stroke and mortality risk after atrial fibrillation ablation: lesson from the CABANA trial
Cristina Balla1, Riccardo Cappato2
1Cardiovascular Center, University of Ferrara, Ferrara, Italy.
Insights
Catheter ablation for atrial fibrillation (AF) did not significantly reduce strokes or death compared to medical therapy. However, ablation improved quality of life and reduced AF recurrences, sparking ongoing clinical debate.
Area of Science:
- Cardiology
- Electrophysiology
- Clinical Trials
Background:
- Atrial fibrillation (AF) is a common arrhythmia impacting quality of life and increasing stroke risk.
- Catheter ablation is an alternative treatment to conventional medical therapy for AF management.
- The optimal treatment strategy for AF remains a subject of clinical debate.
Purpose of the Study:
- To compare the efficacy and safety of catheter ablation versus conventional medical therapy in patients with atrial fibrillation.
- To analyze the impact of catheter ablation on major adverse cardiovascular events, quality of life, and symptom burden.
Main Methods:
- The study was a randomized controlled trial (CABANA trial).
- Participants included patients with symptomatic atrial fibrillation.
- Interventions compared catheter ablation to conventional medical therapy.
Main Results:
- Catheter ablation did not significantly reduce the composite endpoint of stroke, death, or other major adverse events compared to medical therapy.
- Catheter ablation led to a significant reduction in AF recurrences.
- Patients undergoing catheter ablation reported significant improvements in quality of life and symptom relief.
Conclusions:
- The CABANA trial presents mixed results regarding catheter ablation for atrial fibrillation.
- While ablation did not improve major adverse cardiovascular outcomes, it enhanced quality of life and reduced AF burden.
- These findings contribute to the ongoing controversy and discussion on the role of catheter ablation in current AF treatment guidelines.
Abstract:
The CABANA trial is a randomized controlled study comparing catheter ablation vs. conventional medical therapy in atrial fibrillation (AF) patients. The results of the study showed that catheter ablation did not have a significant reduction of strokes, deaths, serious bleeding, or cardiac arrest compared to medical therapy. However, a significant improvement in AF recurrences, quality of life, and symptom relief has been shown after catheter ablation compared to drug therapy. The mixed results of the study emphasized an active controversy in the cardiology community on the interpretation of the data and their use in current clinical practice. In this review, we summarized the principal controversy points of the trial describing the strengths and weaknesses of the study design and analysis.
